RRML - Evaluation of the impact of Covid-19 infection on the evolution and prognosis of patients with acute leukaemia
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17


Advanced search


Top 10 downloaded articles
- September 2022 -
 
Downregulation of hsa-miR-4328... 13
Normality assessment, few para... 10
SPP1 is a biomarker of cervica... 9
Biomarkers in heart failure: f... 7
Expressions of TGF-β1 and VEG... 7
Validation of GOD / PAP method... 6
Approaching Risk Management in... 6
Expression of serum soluble Kl... 6
The effect of Ulva rigida (C. ... 6
Study regarding the use of sal... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 29(4)/2021 DOI:10.2478/rrlm-2021-0032
XML
TXT

Short communication

Evaluation of the impact of Covid-19 infection on the evolution and prognosis of patients with acute leukaemia

Meilin Omer, Ana M. Vladareanu, Viola M. Popov, Mihaela Andreescu, Lelia Iliescu, Horia Bumbea, Serban Dragosloveanu

Correspondence should be addressed to: Viola M Popov

Abstract:

Introduciton: COVID19 is one of the largest pandemics. Since December 2019 until now the coronavirus has infected over 131 million people. The mortality rate in the general population varies between 1 to 5%, with a potential of over 30% in patients with neoplasms. Methods: The main objective of the study was to identify some peculiarities of the evolution, complications and treatment of patients with acute leukaemia and COVID-19. The study was retrospective and included 50 patients with acute leukaemia and COVID-19. Results: Recent administration of chemotherapy was identified in 20 patients with acute myeloblastic leukaemia and 4 patients with acute lymphoblastic leukaemia. The newly diagnosed patients or those undergoing intensive chemotherapy, in particular elderly patients, had a severe form of COVID-19 and an unfavourable evolution, and these clinical situations were identified as predictive factors for adverse outcomes. Patients with acute lymphoblastic leukaemia had a shorter survival curve compared to patients with acute myeloblastic leukaemia. Pneumonia was present especially in patients with acute myeloblastic leukaemia, most patients having over 30% of lung fields affected (55.26%). Patients with an unfavourable outcome had significantly increased median values of C-reactive protein, procalcitonin and interleukin6. Conclusions: Patients with acute leukaemia, especially acute myeloblastic leukaemia who have been diagnosed with COVID-19 infection require special attention because they may associate complications and adverse outcomes of COVID-19. The results we obtained require evaluation in a larger group of patients and analysis in the follow-up period after COVID-19.

Keywords: acute leukemia, COVID-19, chemotherapy, aplasia, respiratory insuficiency

Received: 22.7.2021
Accepted: 1.10.2021
Published: 8.10.2021

 
  PDF Download full text PDF
(878 KB)
     
 
How to cite
Omer M, Vladareanu AM, Popov VM, Andreescu M, Iliescu L, Bumbea H, et al. Evaluation of the impact of Covid-19 infection on the evolution and prognosis of patients with acute leukaemia. Rev Romana Med Lab. 2021;29(4):377-85. DOI:10.2478/rrlm-2021-0032